Compare Heron Therapeutics Inc (HRTX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Verisign, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Verisign, Inc. trades at $272.41 (market cap $25.26B). The key difference: Verisign, Inc. is far larger — about 276.2× Heron Therapeutics Inc's market cap, and Verisign, Inc. pays a 1.17% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | VRSN | |
|---|---|---|
Market Cap | $91.46M | $25.26B |
Sector | Health | Technology |
52-Week High | $1.96 | $310.00 |
52-Week Low | $0.39 | $211.49 |
Enterprise Value | $189.36M | $26.50B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
VeriSign (VRSN) trades at $277.60, down slightly by 0.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 results with EPS of $2.34 beating estimates, driven by 6.6% revenue growth. Analyst consensus is a Buy with a $325.25 price target, reflecting confidence in its domain registry monopoly and robust margins.
Outlook remains positive due to predictable revenue streams from .com and .net domains, though risks include AI disruption and contract renewals. Valuation multiples like P/E of 30.68 appear elevated, requiring sustained growth to justify. Investors should weigh high margins against debt levels and competitive threats for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
